Abnormal expression of GCG has not been reported in any cancer experiments. However, our study showed that GCG was not differentially expressed in overall-stage STAD but was significantly downregulated in the progressive-stage STAD, indicating that GCG might be a novel biomarker of progressive-stage STAD. This evidence concerns the gene GCG and gastric adenocarcinoma.